MUMBAI, India, and BRIDGEWATER, N.J., Sept. 3, 2025 /PRNewswire/ -- Today, OmniActive Health Technologies (OmniActive) announced results from two newly published, peer-reviewed clinical studies in ...
A draft guidance document provides recommendations for submitting bioavailability information in investigational new drug and new drug applications. FDA published draft guidance on Feb. 25, 2019 on ...
To compare the impact of dietary important flavonoids, it is necessary to study them in the same food matrix and at similar realistic doses. The present study investigates the bioavailability and ...
Nanoform has completed the First Subject First Visit in a trial evaluating the relative bioavailability of its nanotechnology-enhanced enzalutamide. Finnish medicine performance enhancing company, ...
Credit: Getty Images. The investigational vesicular monoamine transporter 2 (VMAT2) inhibitor deutetrabenazine (SD-809) can be administered "without regard to the type of meal consumed," according to ...
The US Food and Drug Administration (FDA) released a draft guidance on April 3 providing recommendations to sponsors and testing sites on data integrity for bioavailability and bioequivalence (BA/BE) ...
Objective: Flavanones are polyphenols specific of citrus fruits, where they are present in high amounts. Although citrus fruits and juices are widely consumed in the world, little information has been ...
SPID ®-Technology utilizes compartmentalization to enable sequential release of carbidopa and levodopa, offering a potential new approach for drug delivery in Parkinson’s disease treatment. "Levodopa ...
HELSINKI, Jan. 5, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance enhancing company, today announced it had completed the First Subject First Visit (FSFV) in a trial ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Eli Lilly and Company recently completed ...
(MENAFN- GlobeNewsWire - Nasdaq) Dublin, April 07, 2025 (GLOBE NEWSWIRE) -- The "Bioavailability and Bioequivalence Studies submitted in NDAs and INDs" training has been added to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results